Form 4: BridgeBio Pharma CFO Exercises Options and Sells Shares

BridgeBio Pharma's CFO, Brian C. Stephenson, exercised stock options and sold shares on January 28, 2025, according to a recent SEC filing.

Summary

• Brian C. Stephenson, CFO of BridgeBio Pharma, exercised stock options to acquire 68,000 shares of common stock at $17 per share on January 28, 2025.
• Simultaneously, Mr. Stephenson sold 68,000 shares of common stock at a weighted average price of $36.2906 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 sales plan adopted on March 22, 2024.
• Following these transactions, Mr. Stephenson directly owns 93,758 shares of common stock and 448,670 stock options.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing insider transactions, which is neither positive nor negative in itself. The transactions were pre-planned and expected.

Industry Context

This is a routine filing related to insider transactions and is common for executives of publicly traded companies. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a standard practice among executives at publicly traded companies, including those in the biotechnology sector like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedule of the options, with 48 equal monthly installments, is a typical vesting structure for employee stock options.
• The sale of shares after exercising options is a common way for executives to realize the value of their equity compensation.

Stakeholder Impact

• The transactions may have a minor impact on the stock price due to the sale of shares by a key executive, but this is likely to be minimal given the pre-planned nature of the sales.

Key Dates

Keywords

SEC Form 4, insider trading, stock options, Rule 10b5-1, BridgeBio Pharma, BBIO, Brian C. Stephenson, CFO, share sale